Skip to main content

5 Result(s)

within E. Tabouret Remove this filter

and

  1. No Access

    Article

    Co** with a newly diagnosed high-grade glioma: patient-caregiver dyad effects on quality of life

    Patients with high-grade gliomas (HGG) and their caregivers have to confront a very aggressive disease that produces major lifestyle disruptions. There is an interest in studying the ability of patients and th...

    K. Baumstarck, T. Leroy, Z. Hamidou, E. Tabouret, P. Farina… in Journal of Neuro-Oncology (2016)

  2. Article

    Open Access

    Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152

    Glioblastomas (GBMs) are the most aggressive primary brain tumors in adult and remain a therapeutic challenge. Targeting key apoptosis regulators with the ultimate aim to restore apoptosis in tumor cells could...

    A Tchoghandjian, A Soubéran, E Tabouret, C Colin, E Denicolaï… in Cell Death & Disease (2016)

    Download PDF (2553 KB) View Article

  3. No Access

    Article

    Neuro-oncological patients admitted in intensive-care unit: predictive factors and functional outcome

    The prognosis of oncology patients admitted to the intensive care unit (ICU) is considered poor. Our objective was to analyze the characteristics and predictive factors of death in the ICU and functional outco...

    E. Tabouret, C. Boucard, R. Devillier, M. Barrie, S. Boussen… in Journal of Neuro-Oncology (2016)

  4. No Access

    Article

    Congrès Targeted Anticancer Therapies — TAT 2014

    Les actualités majeures des thérapies ciblées antitumorales se sont discutées lors de la dernière édition du congrès TAT (Targeted Anticancer Therapies) à Washington du 5 au 7 mars 2014. Après l’introduction d...

    A. Bellesoeur, A. Brunot, F. Calcagno, T. Grellety, D. Loirat, E. Tabouret… in Oncologie (2014)

  5. No Access

    Article

    Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen

    Bevacizumab has demonstrated activity in patients with recurrent glioblastoma. However, the impact of prognostic factors associated with recurrent glioblastoma treated with cytotoxic agents has not been determ...

    E. Tabouret, M. Barrie, A. Thiebaut, M. Matta, C. Boucard… in Journal of Neuro-Oncology (2013)